New chemo cocktail shows promise for rare brain tumor patients
NCT ID NCT04755023
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two chemotherapy drugs (BCNU and TMZ) given before radiation therapy in 53 people newly diagnosed with a rare type of brain cancer called anaplastic oligodendroglioma. The goal was to see how well the drugs shrank tumors and to learn more about genetic markers that might predict treatment response. The approach aims to improve disease control and guide future treatment decisions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC OLIGOASTROCYTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Assistance Publique - Hôpitaux de Marseille
Marseille, 13005, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain radiation showdown: proton vs. photon – which saves your mind?
- New combo attack on recurrent brain tumors shows promise in early trial
- Weekly MRI boosts radiation precision for brain cancer patients
- New combo aims to tackle aggressive brain tumors that have come back
- Spinal tap could replace brain surgery for young tumor patients
- Promising drug combo targets Hard-to-Treat brain cancers